FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1996883721> ?p ?o ?g. }

• W1996883721 abstract "Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DCBackground: EGFR overexpression is one of the hallmarks of the “basal-like” TNBC definition by immunohistochemistry (IHC) (Nielsen, 2004). In a phase II neoadjuvant clinical trial targeting EGFR in TNBC, we investigated various biomarkers to better identify an EGFR-sensitive population for potential further regimen development.Methods: Sixty patients (pts) with stage II-IIIA TNBC were prospectively included. Systemic treatment (ST) consisted of the anti-EGFR antibody panitumumab combined with FEC 100, followed by 4 cycles of docetaxel. All pts underwent surgery after ST completion. Patient characteristics: median tumor size: 40 mm (20-120); invasive ductal carcinoma: 96.7%; SBR grade III: 71.7%; complete pathological response (pCR) rate: 46.8% (Chevallier's classification). Paraffin-embedded and frozen tumor samples were collected before and after ST for biologic studies. Germinal BRCA1 mutations, and EGFR, KRAS, BRAF and PI3KCA somatic mutations were analyzed by NGS. EGFR, IGF-1R, MET, cytokeratins 5/6 and 8/18, PTEN, P-cadherin, ALDH1, Ki-67, p53, tumoral FOXP3 expression and the number of FOXP3+ or CD8+ tumor-infiltrating lymphocytes (TILs) were evaluated by IHC. Biopsies and surgical samples were analysed using Affimetrix arrays.Results : By univariate analysis, high CD8+ TILs was response-predictive (pCR rates: CD8 TILs: 84% high vs 10% low; p=3.4.10−6). Tumor FOXP3 expression and high FOXP3 TILs tended to be predictive (pCR rates: tumor FOXP3: 77% positive vs 36% negative, p=0.07; FOXP3 TILs: 66% high vs 37% low, p= 0.08). High IGF-1R expressors responded better than low expressors (80% vs 33%, respectively, p=0.028).As could be expected, a positive correlation between tumor FOXP3 expression and FOXP3 TILs was found (p = 2.7.10−4, r = 0.56). Surprisingly, a positive correlation was found between FOXP3 TILs and CD8+ TILs (p = 2.10−5, r = 0.59) and between tumor FOXP3 and CD8+ TILs (p = 6.3.10−3, r = 0.43).Comparison of EGFR, IGF-1R and Her3 in biopsies versus surgical samples showed reduced EGFR levels in non-responders (p = 0.037), while Her3 (p = 0.049) and IGF-1R (p = 0.08) increased.Sequencing revealed BRCA1 mutations in 10% of pts. No difference of response (pCR) was observed between mutated patients and others (p=0.91). Somatic mutations of PI3K were observed in 6 pts. No mutations were observed in BRAF, KRAS, or EGFR. Analysis of Affymetrix arrays for gene expression is underway and will be presented.Conclusions : Interestingly, the CD8+ TIL count seems to predict the response to panitumumab. Tumor FOXP3 expression and high FOXP3 TILs also tended to be predictive. Tumor levels of IGF-1R seem to play a determinant role in TNBC response to anti-EGFR antibodies, in concordance with our observations in a head-and-neck cancer cohort (Clin Canc Res 2012). Confirmatory and mechanistic studies of those biomarkers are warranted.Citation Format: Frederique Penault-llorca, Catherine Abrial, Marie-Melanie Dauplat, Maud Privat, Nancy Uhrhammer, Alexis Desrichard, Yannick Bidet, Nina Radosevic-Robin, Anne Cayre, Cecile Aube, Fabrice Kwiatkowski, Nassera Chalabi, Yves-Jean Bignon, Philippe Chollet, Jean-Marc Nabholtz. Response to the anti-EGFR antibody panitumumab combined with standard neoadjuvant chemotherapy in triple negative breast cancer (TNBC): the immune and IGFR pathways. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4669. doi:10.1158/1538-7445.AM2013-4669" @default.
• W1996883721 created "2016-06-24" @default.
• W1996883721 creator A5019919654 @default.
• W1996883721 creator A5029086962 @default.
• W1996883721 creator A5041485504 @default.
• W1996883721 creator A5043851603 @default.
• W1996883721 creator A5050906584 @default.
• W1996883721 creator A5054491719 @default.
• W1996883721 creator A5056783002 @default.
• W1996883721 creator A5060027977 @default.
• W1996883721 creator A5061340891 @default.
• W1996883721 creator A5070768873 @default.
• W1996883721 creator A5075866298 @default.
• W1996883721 creator A5077857574 @default.
• W1996883721 creator A5084368181 @default.
• W1996883721 creator A5089414232 @default.
• W1996883721 creator A5090425987 @default.
• W1996883721 date "2013-04-15" @default.
• W1996883721 modified "2023-10-18" @default.
• W1996883721 title "Abstract 4669: Response to the anti-EGFR antibody panitumumab combined with standard neoadjuvant chemotherapy in triple negative breast cancer (TNBC): the immune and IGFR pathways." @default.
• W1996883721 doi "https://doi.org/10.1158/1538-7445.am2013-4669" @default.
• W1996883721 hasPublicationYear "2013" @default.
• W1996883721 type Work @default.
• W1996883721 sameAs 1996883721 @default.
• W1996883721 citedByCount "0" @default.
• W1996883721 crossrefType "proceedings-article" @default.
• W1996883721 hasAuthorship W1996883721A5019919654 @default.
• W1996883721 hasAuthorship W1996883721A5029086962 @default.
• W1996883721 hasAuthorship W1996883721A5041485504 @default.
• W1996883721 hasAuthorship W1996883721A5043851603 @default.
• W1996883721 hasAuthorship W1996883721A5050906584 @default.
• W1996883721 hasAuthorship W1996883721A5054491719 @default.
• W1996883721 hasAuthorship W1996883721A5056783002 @default.
• W1996883721 hasAuthorship W1996883721A5060027977 @default.
• W1996883721 hasAuthorship W1996883721A5061340891 @default.
• W1996883721 hasAuthorship W1996883721A5070768873 @default.
• W1996883721 hasAuthorship W1996883721A5075866298 @default.
• W1996883721 hasAuthorship W1996883721A5077857574 @default.
• W1996883721 hasAuthorship W1996883721A5084368181 @default.
• W1996883721 hasAuthorship W1996883721A5089414232 @default.
• W1996883721 hasAuthorship W1996883721A5090425987 @default.
• W1996883721 hasConcept C121608353 @default.
• W1996883721 hasConcept C126322002 @default.
• W1996883721 hasConcept C143998085 @default.
• W1996883721 hasConcept C190283241 @default.
• W1996883721 hasConcept C203014093 @default.
• W1996883721 hasConcept C2777609662 @default.
• W1996883721 hasConcept C2777701055 @default.
• W1996883721 hasConcept C2778326572 @default.
• W1996883721 hasConcept C2778332735 @default.
• W1996883721 hasConcept C2779727006 @default.
• W1996883721 hasConcept C2780110267 @default.
• W1996883721 hasConcept C2781187634 @default.
• W1996883721 hasConcept C2908647359 @default.
• W1996883721 hasConcept C502942594 @default.
• W1996883721 hasConcept C526805850 @default.
• W1996883721 hasConcept C530470458 @default.
• W1996883721 hasConcept C55493867 @default.
• W1996883721 hasConcept C71924100 @default.
• W1996883721 hasConcept C86554907 @default.
• W1996883721 hasConcept C86803240 @default.
• W1996883721 hasConcept C8891405 @default.
• W1996883721 hasConcept C99454951 @default.
• W1996883721 hasConceptScore W1996883721C121608353 @default.
• W1996883721 hasConceptScore W1996883721C126322002 @default.
• W1996883721 hasConceptScore W1996883721C143998085 @default.
• W1996883721 hasConceptScore W1996883721C190283241 @default.
• W1996883721 hasConceptScore W1996883721C203014093 @default.
• W1996883721 hasConceptScore W1996883721C2777609662 @default.
• W1996883721 hasConceptScore W1996883721C2777701055 @default.
• W1996883721 hasConceptScore W1996883721C2778326572 @default.
• W1996883721 hasConceptScore W1996883721C2778332735 @default.
• W1996883721 hasConceptScore W1996883721C2779727006 @default.
• W1996883721 hasConceptScore W1996883721C2780110267 @default.
• W1996883721 hasConceptScore W1996883721C2781187634 @default.
• W1996883721 hasConceptScore W1996883721C2908647359 @default.
• W1996883721 hasConceptScore W1996883721C502942594 @default.
• W1996883721 hasConceptScore W1996883721C526805850 @default.
• W1996883721 hasConceptScore W1996883721C530470458 @default.
• W1996883721 hasConceptScore W1996883721C55493867 @default.
• W1996883721 hasConceptScore W1996883721C71924100 @default.
• W1996883721 hasConceptScore W1996883721C86554907 @default.
• W1996883721 hasConceptScore W1996883721C86803240 @default.
• W1996883721 hasConceptScore W1996883721C8891405 @default.
• W1996883721 hasConceptScore W1996883721C99454951 @default.
• W1996883721 hasLocation W19968837211 @default.
• W1996883721 hasOpenAccess W1996883721 @default.
• W1996883721 hasPrimaryLocation W19968837211 @default.
• W1996883721 hasRelatedWork W1517129146 @default.
• W1996883721 hasRelatedWork W1984103379 @default.
• W1996883721 hasRelatedWork W2022922468 @default.
• W1996883721 hasRelatedWork W2080138326 @default.
• W1996883721 hasRelatedWork W2331071950 @default.
• W1996883721 hasRelatedWork W2489546560 @default.
• W1996883721 hasRelatedWork W2548763762 @default.
• W1996883721 hasRelatedWork W2592833514 @default.
• W1996883721 hasRelatedWork W2740164441 @default.
• W1996883721 hasRelatedWork W2740455593 @default.
• W1996883721 hasRelatedWork W2791150505 @default.
• W1996883721 hasRelatedWork W2791253455 @default.

• next